BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
BeOne Medicines Ltd. - American Depositary Shares (ONC)
Company Research
Source: Business Wire
Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periodsGlobal BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periodsDiluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full yearFull year 2026 total revenue guidance of $6.2 billion to $6.4 billion SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.“These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical deve
Show less
Read more
Impact Snapshot
Event Time:
ONC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONC alerts
High impacting BeOne Medicines Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ONC
News
- BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion [Yahoo! Finance]Yahoo! Finance
- BeOne Medicines (ONC) had its price target raised by Truist Financial Corporation from $400.00 to $412.00. They now have a "buy" rating on the stock.MarketBeat
- BeOne Medicines (ONC) had its price target raised by Guggenheim from $400.00 to $410.00. They now have a "buy" rating on the stock.MarketBeat
- BeOne Medicines (ONC) had its price target raised by Barclays PLC from $394.00 to $405.00. They now have an "overweight" rating on the stock.MarketBeat
- BeOne Medicines (ONC) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
ONC
Earnings
- 2/26/26 - Beat
ONC
Sec Filings
- 2/6/26 - Form 4
- 1/9/26 - Form 4
- 1/5/26 - Form 4
- ONC's page on the SEC website